NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $11.64 -0.39 (-3.24%) As of 03:45 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Keros Therapeutics Stock (NASDAQ:KROS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Keros Therapeutics alerts:Sign Up Key Stats Today's Range$11.13▼$12.1950-Day Range$9.91▼$12.0752-Week Range$9.69▼$22.55Volume153,114 shsAverage Volume368,964 shsMarket Capitalization$230.36 millionP/E RatioN/ADividend YieldN/APrice Target$20.40Consensus RatingHold Company Overview Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need. The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis. KER-050 is currently being evaluated in multiple clinical trials across North America and Europe. In parallel, Keros is advancing additional preclinical programs that leverage its proprietary platform to address other hematologic and iron-related disorders. Founded in 2019 as a spin-out from academic research, Keros Therapeutics is headquartered in Boston, Massachusetts, and collaborates with leading research institutions and clinical centers worldwide. The company’s leadership team comprises industry veterans in research and development, clinical operations and regulatory affairs, all focused on translating groundbreaking science into therapies that improve patient outcomes in serious blood diseases.AI Generated. May Contain Errors. Read More Keros Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreKROS MarketRank™: Keros Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 398th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingKeros Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialKeros Therapeutics has a consensus price target of $20.40, representing about 76.5% upside from its current price of $11.56.Amount of Analyst CoverageKeros Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Keros Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.19) to ($5.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Keros Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.96% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Keros Therapeutics has recently decreased by 6.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have sold 311.12% more of their company's stock than they have bought. Specifically, they have bought $21,890.00 in company stock and sold $89,994.00 in company stock.Percentage Held by Insiders20.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KROS Stock News HeadlinesKeros Therapeutics’ TROPOS Trial Termination: What It Means for KROS InvestorsJuly 2, 2026 | tipranks.comKeros Therapeutics Appoints Anne Prener to its Board of DirectorsJune 25, 2026 | globenewswire.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.July 10 at 1:00 AM | Porter & Company (Ad)Jean Jacques Bienaime Acquires 1,000 Shares of Keros Therapeutics (NASDAQ:KROS) StockJune 18, 2026 | insidertrades.comKROS Share News TodayJune 14, 2026 | uk.investing.comKeros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comBank of America Securities Reaffirms Their Hold Rating on Keros Therapeutics (KROS)June 5, 2026 | theglobeandmail.comKeros Therapeutics CEO to Present at Goldman Sachs ConferenceJune 2, 2026 | theglobeandmail.comSee More Headlines KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $20.36 at the start of the year. Since then, KROS shares have decreased by 43.2% and is now trading at $11.56. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by $0.19. The business had revenue of $0.37 million for the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative trailing twelve-month return on equity of 17.04% and a negative net margin of 256.60%. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $90 million in an initial public offering on Wednesday, April 8th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings5/14/2026Today7/10/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 KROS's financial health is in the Red zone, according to TradeSmith. KROS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KROS CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees100Year Founded2015Price Target and Rating Average Price Target for Keros Therapeutics$20.40 High Price Target$27.00 Low Price Target$16.00 Potential Upside/Downside+75.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$87.01 million Net Margins-256.60% Pretax Margin-272.15% Return on Equity-17.04% Return on Assets-15.84% Debt Debt-to-Equity RatioN/A Current Ratio22.61 Quick Ratio22.62 Sales & Book Value Annual Sales$244.06 million Price / Sales0.94 Cash Flow$4.51 per share Price / Cash Flow2.58 Book Value$15.51 per share Price / Book0.75Miscellaneous Outstanding Shares19,790,000Free Float15,715,000Market Cap$230.47 million OptionableOptionable Beta0.97 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:KROS) was last updated on 7/10/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredExecutive order could send gold to 6,000 per ounceExecutive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...Cedar Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
